Register for an account


Enter your name and email address below.

Your email address is used to log in and will not be shared or sold. Read our privacy policy.


Website access code

Enter your access code into the form field below.

If you are a Zinio, Nook, Kindle, Apple, or Google Play subscriber, you can enter your website access code to gain subscriber access. Your website access code is located in the upper right corner of the Table of Contents page of your digital edition.


Rewind, Replay, Research Disease

Old blood samples turn into new stem cells that replicate patient pathology.

By Caleb OBrienOctober 1, 2015 5:00 AM
Induced pluripotent stem cells grown from blood (left) are nearly identical to those grown more easily from skin (right). | Stem Cells Translational Medicine/Alpha Med Press/doi: 10.5966/sctm.2014-0121/reprinted with permission


Sign up for our email newsletter for the latest science news

They had blood, but they wanted guts.

Researchers at Cedars-Sinai Medical Center in Los Angeles had access to thousands of blood samples and detailed clinical records collected from patients over decades. But the diseases that they wanted to study — including inflammatory bowel disease and spinal muscular atrophy — generally did not affect blood cells.

Faced with this quandary, the team spent nearly three years devising a technique to reliably transform what they did have — blood — into induced pluripotent stem cells, or iPSCs. These stem cells, which are similar to highly sought-after embryonic stem cells but derived from adult cells and then reprogrammed, could be turned into the cell types needed for research, including neurons and intestinal and fat cells.

Transforming blood cells into iPSCs is more complex than other methods, such as using a patient’s skin cells. In the new technique, cells are redirected by introducing a complex cocktail of seven different genes, known as reprogramming factors.

Researchers have already developed dozens of patient-specific cell lines using this new method. Dhruv Sareen, director of the Cedars-Sinai iPSC Core Facility, says the procedure allows researchers to essentially replicate the conditions and trajectory of an individual’s illness: “It’s like replaying the patient’s disease in the dish.”

    3 Free Articles Left

    Want it all? Get unlimited access when you subscribe.


    Already a subscriber? Register or Log In

    Want unlimited access?

    Subscribe today and save 50%


    Already a subscriber? Register or Log In